Category Archives: EirGenix
[Taipei, Taiwan] – For the Phase III clinical trial of its breast cancer drug EG12014 (Trastuzumab biosimilar, also called EGI014), EirGenix, Inc. (6589.TT) has completed neoadjuvant treatment and surgery of its last patient. Following analysis of the main efficacy data (pathological complete response [pCR] at the time of surgery) for all patients in the Phase III clinical trial, EG12014 will be compared with the originator drug (Roche’s Herceptin®) to confirm bioequivalence.
On September 25th, the Indian Council for Medical Research (ICMR) announced that it has validated and approved Vstrip® COVID-19 Antigen Rapid Test as satisfactory and meets the minimum acceptance criteria of sensitivity and specificity of rapid antigen test kits.
[Taipei, Taiwan] – After completion of its first and second licensing agreement milestones for its breast cancer biosimilar, EG12014 (Trastuzumab Biosimilar, also called EGI014), EirGenix, Inc. (6589.TT) has completed its third licensing agreement milestone today.
- 1
- 2